Physician profile
Dinu Cherian
NPI 1851550388
$2,479.98
in general payments reported to CMS, 2019-2025
26 companies · $811 in 2025
The $811 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $14.15 · 2021: $161 · 2022: $252 · 2023: $298 · 2024: $805 · 2025: $811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,913.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $610.37 | 2021-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $499.16 | 2021-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $190.97 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $186.30 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.10 | 2023-2025 | Xifaxan, Plenvu |
| Celgene Corporation | $134.34 | 2021-2024 | Zeposia |
| Micro-Tech Endoscopy USA, INC. | $95.04 | 2023-2025 | Lesion Huntr, Blueboost, Sureclip |
| Ipsen Biopharmaceuticals, INC | $71.69 | 2025 | Iqirvo |
| Genzyme Corporation | $57.73 | 2025 | |
| Phathom Pharmaceuticals, INC. | $56.74 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $56.35 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $52.40 | 2025 | Rezdiffra |
| Lilly USA, LLC | $40.01 | 2024-2025 | Omvoh |
| Capsovision, INC. | $35.17 | 2023-2024 | Capsocam Plus |
| Qol Medical, LLC | $32.26 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $28.41 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $25.00 | 2024 | |
| Daiichi Sankyo INC. | $24.34 | 2021 | |
| Axonics, INC. | $24.21 | 2022 | |
| Novo Nordisk INC | $23.60 | 2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $21.36 | 2023 | Andexxa |
| Evoke Pharma, INC. | $18.07 | 2025 | |
| Shionogi INC | $17.08 | 2019 | |
| Merck Sharp & Dohme LLC | $14.84 | 2024 | Dificid |
| Medtronic, INC. | $14.66 | 2023 | Gi Genius |
| Olympus America INC. | $13.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dinu Cherian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.